Law Offices of Thomas J. Lamb

  • About Our Firm
  • Drug Injury
  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Breast Implants
  • Free Case Evaluation
  • FAQs

Gadolinium Deposition Disease can Result from use of Contrast Agents During MRI & MRA Procedures

February 23, 2018 By Law Offices of Thomas J. Lamb, P.A.


What are Gadolinium-Based Contrast Agents (GBCAs)?

GBCAs are substances that are injected into patients during Magnetic Resonance Imaging (MRI) or Magnetic Resonance Angiography (MRA) in order to produce clearer radiology images.

Here is a list of GBCAs that are currently approved by the FDA:

  • Ablavar
  • Dotarem
  • Eovist
  • Gadavist
  • Magnevist
  • MultiHance
  • Omniscan
  • OptiMARK
  • ProHance

These substances contain gadolinium, a toxic synthetic heavy metal, which is bonded to a linear or macrocyclic compound in order to reduce toxicity.

While the bonding compounds are designed to help usher gadolinium out of the body, sometimes the bonds break and gadolinium is left behind in the bones, brain, and various tissues within the body.

 

What can happen when Gadolinium remains in the body?

Several conditions can occur as a result of gadolinium retention:

  • Nephrogenic systemic fibrosis (NSF)
  • Gadolinium storage condition
  • Gadolinium deposition disease

NSF occurs in patients with renal insufficiency.  In these patients, gadolinium cannot be removed from the body adequately as a result of decreased kidney function.  As a result, thickening and darkening of the skin, shortening of the muscles and tendons, and other symptoms can occur.  This condition can potentially be fatal.

Gadolinium storage condition is the excess of gadolinium in patients with normal renal function.

Gadolinium deposition disease occurs when a patient has an excess of gadolinium in their system, but they have normal or adequate renal function. Symptoms of this condition can manifest anywhere from a few hours to several weeks after the GBCA injection was administered, and are as follows:

  • Persistent headache
  • Severe pain in the bones, joints, arms, and legs
  • Sensation of sharp pins and needles, cutting, or burning
  • Cognitive impairment
  • Clouded mentation (“brain fog”)
  • Nausea / vomiting
  • Thickening of soft-tissue, tendons, and ligaments
  • Tightness in the hands and feet

 

What actions are being taken?

Regulatory agencies here and abroad have taken steps to warn patients about the potential for gadolinium retention as a result of GBCA use.

In my next article, I will further discuss the specific regulatory actions that have occurred over the years.  I will also discuss the current status of this situation in the U.S. as well as in Europe.

Rest assured that we will continue to monitor the medical literature concerning the risk of NSF and gadolinium deposition disease as a result of GBCA use during MRI and MRA procedures, and report on any significant developments.

 

Written by: Heather Helmendach, Legal Assistant 
Law Offices of Thomas J. Lamb, P.A.

 


Gadolinium-Containing Contrast Agents

Free Case Evaluation

Strictly Confidential, No Obligation


 

Drug Injury Watch: Side Effects News & Reports

Drug Injury Law: Medical & Legal Information

 

Filed Under: Unsafe Drugs Tagged With: Ablavar, Dotarem, Eovist, Gadavist, gadolinium, Gadolinium deposition disease, gadolinium retention, Gadolinium storage condition, gadolinium-based contrast agents, GBCAs, Magnevist, mra contrast agents side effects, mri contrast agents side effects, MultiHance, Nephrogenic systemic fibrosis, NSF, Omniscan, OptiMARK, ProHance

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Either way, you will get Mr. Lamb’s impressions about your case — and not that of a junior lawyer, paralegal, or (worse yet) some case-intake person.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • Drug Injury Cases
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • GenX Cancer Cases
  • Breast Implant Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • About Our Firm
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Attorney Tom Lamb

Mr. Lamb is recognized by other lawyers as practicing law at the highest level of professional experience in terms of legal ability and ethical standards — which is indicated by an AV® Preeminent™ 5.0 out of 5 rating (highest classification) rating from the Martindale-Hubbell® Lawyer Directory.

More importantly, he received the Martindale-Hubbell® Client Distinction Award, which recognizes excellence for:

Quality of Service
Overall Value
Responsiveness
Communication Ability

Read More About Tom Lamb

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma
Asbestos HUB

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2019 · Law Offices of Thomas J. Lamb, P.A.